Bionano Genomics Past Earnings Performance
Past criteria checks 0/6
Bionano Genomics's earnings have been declining at an average annual rate of -47.1%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 30.2% per year.
Key information
-47.1%
Earnings growth rate
45.1%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 30.2% |
Return on equity | -241.8% |
Net Margin | -643.7% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower
May 09Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%
Mar 14Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn
Oct 18Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests
Sep 23Bionano jumps 36% as publication highlights optical genome mapping
Aug 11Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss
Aug 04Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities
Jun 29I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics
Jun 23Here's Why We're Not Too Worried About Bionano Genomics' (NASDAQ:BNGO) Cash Burn Situation
Apr 11Revenue & Expenses BreakdownBeta
How Bionano Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 36 | -232 | 95 | 54 |
30 Sep 23 | 34 | -227 | 99 | 56 |
30 Jun 23 | 32 | -147 | 97 | 55 |
31 Mar 23 | 30 | -140 | 92 | 52 |
31 Dec 22 | 28 | -133 | 86 | 49 |
30 Sep 22 | 26 | -117 | 81 | 44 |
30 Jun 22 | 23 | -106 | 76 | 38 |
31 Mar 22 | 21 | -92 | 68 | 30 |
31 Dec 21 | 18 | -72 | 57 | 22 |
30 Sep 21 | 16 | -61 | 47 | 16 |
30 Jun 21 | 13 | -51 | 40 | 12 |
31 Mar 21 | 11 | -41 | 32 | 10 |
31 Dec 20 | 9 | -41 | 30 | 10 |
30 Sep 20 | 7 | -37 | 28 | 10 |
30 Jun 20 | 8 | -33 | 23 | 10 |
31 Mar 20 | 9 | -32 | 23 | 10 |
31 Dec 19 | 10 | -30 | 20 | 9 |
30 Sep 19 | 11 | -28 | 18 | 10 |
30 Jun 19 | 11 | -27 | 17 | 10 |
31 Mar 19 | 12 | -23 | 16 | 9 |
31 Dec 18 | 12 | -18 | 14 | 9 |
30 Sep 18 | 11 | -18 | 13 | 9 |
30 Jun 18 | 11 | -18 | 13 | 10 |
31 Mar 18 | 10 | -22 | 14 | 11 |
31 Dec 17 | 10 | -23 | 14 | 12 |
31 Dec 16 | 7 | -19 | 13 | 11 |
Quality Earnings: BNGO is currently unprofitable.
Growing Profit Margin: BNGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNGO is unprofitable, and losses have increased over the past 5 years at a rate of 47.1% per year.
Accelerating Growth: Unable to compare BNGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNGO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: BNGO has a negative Return on Equity (-241.78%), as it is currently unprofitable.